[go: up one dir, main page]

BRPI0410875A - método de inibição do crescimento de tumor com anticorpos de fator antitecido - Google Patents

método de inibição do crescimento de tumor com anticorpos de fator antitecido

Info

Publication number
BRPI0410875A
BRPI0410875A BRPI0410875-2A BRPI0410875A BRPI0410875A BR PI0410875 A BRPI0410875 A BR PI0410875A BR PI0410875 A BRPI0410875 A BR PI0410875A BR PI0410875 A BRPI0410875 A BR PI0410875A
Authority
BR
Brazil
Prior art keywords
growth inhibition
inhibition method
factor growth
tumor factor
tumor growth
Prior art date
Application number
BRPI0410875-2A
Other languages
English (en)
Inventor
Glenn M Anderson
Richard Tawadros
Cam Ngo
Marian Nakada
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of BRPI0410875A publication Critical patent/BRPI0410875A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MéTODO DE INIBIçãO DO CRESCIMENTO DE TUMOR COM ANTICORPOS DE FATOR ANTITECIDO". A presente invenção refere-se a um método de uso dos antagonistas de fator de tecido para tratar doenças proliferativas, caracterizado pela neovascularização tal como câncer, artrite reumatóide, psoríase, ou retinopatia proliferativa, ou degeneração macular. Os antagonistas de fator de tecido, capazes de prevenção rápida da coagulação sangüínea através das trilhas extrínsecas são também capazes de inibir o crescimento de tumor nos mamíferos.
BRPI0410875-2A 2003-05-30 2004-05-27 método de inibição do crescimento de tumor com anticorpos de fator antitecido BRPI0410875A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47517403P 2003-05-30 2003-05-30
PCT/US2004/016663 WO2004110363A2 (en) 2003-05-30 2004-05-27 Method of inhibiting tumor growth with anti-tissue factor antibodies

Publications (1)

Publication Number Publication Date
BRPI0410875A true BRPI0410875A (pt) 2006-07-04

Family

ID=33551529

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410875-2A BRPI0410875A (pt) 2003-05-30 2004-05-27 método de inibição do crescimento de tumor com anticorpos de fator antitecido

Country Status (9)

Country Link
US (1) US20050031615A1 (pt)
EP (1) EP1633309A4 (pt)
JP (1) JP2006526641A (pt)
KR (1) KR20060035608A (pt)
CN (1) CN100528229C (pt)
BR (1) BRPI0410875A (pt)
CA (1) CA2527621A1 (pt)
NO (1) NO20056216L (pt)
WO (1) WO2004110363A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1735011A4 (en) * 2004-04-16 2008-03-26 Scripps Research Inst METHOD FOR VASCULARIZATION MODULATION
JP2009508476A (ja) 2005-08-31 2009-03-05 セントカー・インコーポレーテツド 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
NZ604718A (en) 2010-06-15 2015-01-30 Genmab As Human antibody drug conjugates against tissue factor
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CN107011440B (zh) 2011-05-13 2021-03-05 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
CN104056267A (zh) * 2013-03-18 2014-09-24 苏州纳诺康生物技术有限公司 用组织因子抗体提高乳腺癌内分泌药物治疗效果的方法
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2021200131A1 (ja) * 2020-03-30 2021-10-07 国立研究開発法人国立がん研究センター 抗体薬物複合体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
WO1994028017A1 (en) * 1993-06-01 1994-12-08 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
CA2223491C (en) * 1995-06-07 2010-08-10 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
CA2325346A1 (en) * 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
US6703494B2 (en) * 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
KR20040045478A (ko) * 2001-10-02 2004-06-01 노보 노르디스크 에이/에스 인간 조직인자 항체
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof

Also Published As

Publication number Publication date
WO2004110363A2 (en) 2004-12-23
KR20060035608A (ko) 2006-04-26
CN1829531A (zh) 2006-09-06
JP2006526641A (ja) 2006-11-24
CN100528229C (zh) 2009-08-19
CA2527621A1 (en) 2004-12-23
WO2004110363A3 (en) 2006-05-11
NO20056216L (no) 2006-02-24
EP1633309A2 (en) 2006-03-15
US20050031615A1 (en) 2005-02-10
EP1633309A4 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
BRPI0410875A (pt) método de inibição do crescimento de tumor com anticorpos de fator antitecido
BR0112038A (pt) Triazolopirimidinas substituìdas como agentes anticâncer
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
BR112019023758A2 (pt) vírus da doença newcastle e seus usos
BRPI0608175A2 (pt) método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
MX9702530A (es) Ligandos tie-2, metodos de preparacion y usos de los mismos.
BRPI0406834A (pt) Tratamento de doença com agonistas totais do receptor nach alfa-7
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
EA200970387A1 (ru) Соль п-толуолсульфокислоты 5-амино-3-(2`-о-ацетил-3`-дезокси-бета-d-рибофуранозил)-3н-тиазоло[4,5-d]пиримидин-2-она и способы получения
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
BRPI0414736A (pt) 5-aril-pirimidinas como agentes anticáncer
ATE514718T1 (de) Peptabody für krebsbehandlung
BRPI0414700A (pt) 6-[(substituìdo)fenil]triazolopirimidinas como agentes anti-cáncer
WO2006014999A3 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
BR0309456A (pt) agentes de proliferação de células

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL